Prevacid® SoluTab™ (lansoprazole) – First-time generic

- **On March 8, 2018, Teva launched AB-rated generic versions of Takeda’s Prevacid SoluTab (lansoprazole) 15 mg and 30 mg delayed-release orally disintegrating tablets.**

- Prevacid SoluTab is approved for the following (consult the Prevacid SoluTab drug label for detailed information about the indications):
  
  - Treatment of active duodenal ulcer
  - Eradication of *Helicobacter pylori* to reduce the risk of duodenal ulcer recurrence
  - Maintenance of healed duodenal ulcers
  - Treatment of active benign gastric ulcer
  - Healing of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric ulcer
  - Risk reduction of NSAID-associated gastric ulcer
  - Treatment of symptomatic gastroesophageal reflux disease (GERD)
  - Treatment of erosive esophagitis (EE)
  - Maintenance of healing of EE
  - Pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES).

- Lansoprazole is also available generically as **15 mg and 30 mg delayed-release capsules, over-the-counter (OTC) 15 mg delayed-release capsules, and 30 mg delayed-release capsules in combination with amoxicillin and clarithromycin.**

  - Generic lansoprazole carries the same indications as Prevacid SoluTab.
  - Generic OTC lansoprazole is used to treat frequent heartburn (occurs 2 or more days a week).
  - The combination therapy is approved for *H. pylori* eradication to reduce the risk of duodenal ulcer recurrence.